Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.46 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | DRD2 | P14416 | 1/20 | 0.40 |
| ▸ | DRD4 | P21917 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.40 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.40 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 2/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5689359 | 1.00 | MRGPRX4 (0.46) | MRGPRX4MCHR1KDM4EDRD2DRD4 | |
| SCHEMBL5690074 | 0.92 | KDM4E (0.49) | MRGPRX4MCHR1KDM4EKCNH2CYP3A4 | |
| SCHEMBL5690071 | 0.92 | KDM4E (0.49) | MRGPRX4MCHR1KDM4EKCNH2CYP3A4 | |
| SCHEMBL5690106 | 0.91 | KDM4E (0.46) | MRGPRX4MCHR1KDM4EKCNH2CYP3A4 | |
| SCHEMBL5689670 | 0.91 | KDM4E (0.46) | MRGPRX4MCHR1KDM4EKCNH2CYP3A4 | |
| SCHEMBL5689665 | 0.91 | KDM4E (0.46) | MRGPRX4MCHR1KDM4EKCNH2CYP3A4 | |
| SCHEMBL5690113 | 0.86 | CHRNB2 (0.44) | KDM4EDRD4 | |
| SCHEMBL5690120 | 0.86 | CHRNB2 (0.44) | KDM4EDRD4 | |
| SCHEMBL5689857 | 0.85 | KDM4E (0.45) | MRGPRX4KDM4EKCNH2CYP3A4CYP2C9 | |
| SCHEMBL5689775 | 0.85 | KDM4E (0.45) | MRGPRX4KDM4EKCNH2CYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0982026-B1 | Use of aryl-cyclohexylamine derivatives in the manufacture of NMDA receptor blockers | HOFFMANN LA ROCHE (CH) | 2006-05-17 | — | — | EP | disclosed |
| US-6184236-B1 | Method of treating a neurodegenerative disease by administering an aryl-cyclohexylamine derivative | HOFFMANN-LA ROCHE INC. | 2001-02-06 | — | — | US | disclosed |
| EP-0982026-A2 | Use of aryl-cyclohexylamine derivatives in the manufacture of NMDA receptor blockers | F. HOFFMANN-LA ROCHE AG (CH) | 2000-03-01 | — | — | EP | disclosed |